Praxis Precision Medicines, Inc. PRAX Business Segments — Total stock-based compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s business segments — total stock-based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s business segments — total stock-based compensation expense?
- Praxis Precision Medicines, Inc. (PRAX) reported business segments — total stock-based compensation expense of $17.11M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s business segments — total stock-based compensation expense changed year-over-year?
- Praxis Precision Medicines, Inc.'s business segments — total stock-based compensation expense increased by 94.8% year-over-year, from $8.79M to $17.11M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s business segments — total stock-based compensation expense?
- Over 2 years (2023 to 2025), Praxis Precision Medicines, Inc.'s business segments — total stock-based compensation expense has grown at a 16.9% compound annual growth rate (CAGR), from $24.86M to $33.94M.
- What does business segments — total stock-based compensation expense mean?
- The non-cash cost of equity-based compensation provided to employees and directors.
- How do you interpret business segments — total stock-based compensation expense?
- Higher levels indicate significant use of equity for talent retention, while lower levels may suggest a shift toward cash-based incentives or reduced award grants.
- How does business segments — total stock-based compensation expense compare across companies?
- Standard line item for all publicly traded companies, especially those in high-growth biotech sectors.